What is the 13F Pro Quality Score for IDYA?

13F Pro ranks IDEAYA Biosciences, Inc. (IDYA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IDYA's current score at https://13fpro.ai/company/IDYA (free sign-up required for the full ranking).

Which hedge funds own the most IDYA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IDYA include FMR, BlackRock,, Jupiter Topco. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IDYA as soon as new 13F filings post.

Where does 13F Pro source IDYA data?

All IDEAYA Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. IDEAYA Biosciences, Inc. files with the SEC under CIK 1676725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IDYA in?

IDEAYA Biosciences, Inc. (IDYA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IDYA research updated on 13F Pro?

IDYA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IDEAYA Biosciences, Inc.(IDYA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1676725 IDYA stock profile & AI dashboard →

13F Pro Quality Score

36.1/100

Rank #2,280 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

98.2/100

Profitability

8.8/100

Balance Sheet

13.4/100

Earnings Quality

29.5/100

Free Cash Flow

9.4/100

Institutional Flow

12.9/100

Revenue Scale

25.6/100

Dilution Risk

8.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IDYA Scores 36/100

exact factor attribution · 2026-09-11

IDYA's composite is driven by revenue growth and earnings growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.6 pts

98th pct

Earnings growth

+2.0 pts

91th pct

Institutional flow

-1.9 pts

13th pct

Earnings quality

-2.0 pts

30th pct

Shareholder dilution

-2.1 pts

9th pct

Capital efficiency

-3.7 pts

13th pct

Scale

-3.7 pts

26th pct

Free cash flow

-6.1 pts

9th pct

Profitability

-6.2 pts

9th pct

Latest change (2026-08-05): 10 → 15 · ↑ Revenue growth 3→25

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IDYA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IDEAYA Biosciences, Inc. (IDYA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IDYA at 36.1/100 on a 32-signal composite quality model, placing it at rank #2,280 of 2,962 stocks — the bottom half of the AI-ranked universe. IDYA scores in the top quartile across revenue growth (98.2). Areas of concern include profitability (8.8) and free cash flow (9.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IDEAYA Biosciences, Inc. reports quarterly revenue of $8.9M, net income of $-112.5M, free cash flow of $-89.1M. Top institutional holders of IDYA by reported 13-F value include FMR, BlackRock, Jupiter Topco, based on the most recent SEC filings. IDYA trades on the Nasdaq exchange and files with the SEC under CIK 1676725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IDYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IDEAYA Biosciences, Inc. directly from SEC EDGAR. IDEAYA Biosciences, Inc.'s 13F Pro composite quality score has ranged between 8 and 40 since 2021, currently 36.1 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.

✦

Fun facts about IDEAYA Biosciences, Inc.

Quirks, history, and lore behind IDYA — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco · focused on precision oncology.
2
The Numbers
A small-cap biotech with minimal product revenue — it runs largely on collaboration payments and milestones from partnerships with larger pharma companies.
3
The History
Founded around 2015, it was built from the ground up to pursue synthetic lethality — the idea that cancer cells with certain mutations can be killed by disabling a second, compensating pathway.
4
The Secret
Its pipeline targets DNA damage response vulnerabilities in tumors, with programs aimed at cancers driven by mutations like GNAQ/GNA11 — a rare angle that most big oncology players overlook.
5
The Lore
It landed a significant collaboration deal with GSK, giving it both validation and cash runway while it advances multiple candidates through trials — a neat trick for a young biotech.
6
The Giveaway
Its name is a riff on the word idea, its ticker is IDYA, and its lead program targets uveal melanoma — one of the rarest and hardest-to-treat cancers out there.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$8.9M

Net Income

Q2 2026

$-112.5M

Free Cash Flow

Q2 2026

$-89.1M

ROIC

Q2 2026

-40.8%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+3024.4% YoY

$218.7MFY 2025

FY22 $50.9MFY23 $23.4MFY24 $7.0MFY25 $218.7M

Net Income

+58.6% YoY

$-113.7MFY 2025

FY22 $-58.7MFY23 $-113.0MFY24 $-274.5MFY25 $-113.7M

Operating Income

+51.3% YoY

$-159.3MFY 2025

FY22 $-62.5MFY23 $-134.4MFY24 $-327.0MFY25 $-159.3M

EPS (Diluted)

+61.9% YoY

$-1.28FY 2025

FY22 $-1.42FY23 $-1.96FY24 $-3.36FY25 $-1.28

Total Assets

-1.3% YoY

$1.11BFY 2025

FY22 $388.0MFY23 $649.3MFY24 $1.12BFY25 $1.11B

Op. Cash Flow

+71.3% YoY

$-71.1MFY 2025

FY22 $-87.2MFY23 $-115.2MFY24 $-247.6MFY25 $-71.1M

Free Cash Flow

+70.8% YoY

$-73.5MFY 2025

FY22 $-90.6MFY23 $-117.6MFY24 $-251.4MFY25 $-73.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$218.7M +3024.4%	$7.0M -70.1%	$23.4M -54.1%	$50.9M +82.3%	$27.9M +43.0%	$19.5M
Net Income	$-113.7M +58.6%	$-274.5M -143.0%	$-113.0M -92.6%	$-58.7M -17.9%	$-49.8M -44.3%	$-34.5M
Operating Income	$-159.3M +51.3%	$-327.0M -143.2%	$-134.4M -115.1%	$-62.5M -24.3%	$-50.3M -42.2%	$-35.3M
EPS (Diluted)	$-1.28 +61.9%	$-3.36 -71.4%	$-1.96 -38.0%	$-1.42 -0.7%	$-1.41 -0.7%	$-1.40
Total Assets	$1.11B -1.3%	$1.12B +73.1%	$649.3M +67.4%	$388.0M +1.7%	$381.3M +27.9%	$298.3M
Operating Cash Flow	$-71.1M +71.3%	$-247.6M -114.9%	$-115.2M -32.2%	$-87.2M -56.3%	$-55.8M -200.6%	$55.5M
Free Cash Flow	$-73.5M +70.8%	$-251.4M -113.8%	$-117.6M -29.8%	$-90.6M -55.1%	$-58.4M -206.3%	$55.0M

Get alerted when IDYA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IDEAYA Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IDYA

FMR LLC
$525.9M14,109,431 sh
BlackRock, Inc.
$331.5M8,893,260 sh
Jupiter Topco LLC
$319.7M8,579,881 sh
Capital Research Global Investors
$199.2M5,344,701 sh
BAKER BROS. ADVISORS LP
$186.7M5,010,030 sh
STATE STREET CORP
$169.5M4,548,911 sh
VANGUARD CAPITAL MANAGEMENT LLC
$154.0M4,132,646 sh
Logos Global Management LP
$111.8M3,000,000 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$101.2M2,715,391 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$101.2M2,714,503 sh

Fund	Value	Shares
FMR LLC	$525.9M	14,109,431
BlackRock, Inc.	$331.5M	8,893,260
Jupiter Topco LLC	$319.7M	8,579,881
Capital Research Global Investors	$199.2M	5,344,701
BAKER BROS. ADVISORS LP	$186.7M	5,010,030
STATE STREET CORP	$169.5M	4,548,911
VANGUARD CAPITAL MANAGEMENT LLC	$154.0M	4,132,646
Logos Global Management LP	$111.8M	3,000,000
ADAGE CAPITAL PARTNERS GP, L.L.C.	$101.2M	2,715,391
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$101.2M	2,714,503

Companies Similar to IDYA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

DNTH

Dianthus Therapeutics, Inc. /DE/

AI score

Very similar · 24 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)BAKER BROS. ADVISORS LP Logos Global Management LP

WVE

Wave Life Sciences, Inc.

AI score

Very similar · 17 shared holders

GSK plc RTW INVESTMENTS, LP abrdn plc

STOK

Stoke Therapeutics, Inc.

AI score

Very similar · 17 shared holders

BAKER BROS. ADVISORS LP DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Redmile Group, LLC

NRIX

Nurix Therapeutics, Inc.

AI score

Very similar · 20 shared holders

BAKER BROS. ADVISORS LP Redmile Group, LLC Affinity Asset Advisors, LLC

QURE

uniQure N.V.

AI score

Very similar · 20 shared holders

Fiera Capital Corp abrdn plc Affinity Asset Advisors, LLC

RCUS

Arcus Biosciences, Inc.

AI score

Very similar · 19 shared holders

Sofinnova Ventures Inc BAKER BROS. ADVISORS LP Candriam S.C.A.

TNGX

Tango Therapeutics, Inc.

AI score

Very similar · 24 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Logos Global Management LP Candriam S.C.A.

XNCR

Xencor Inc

AI score

Very similar · 11 shared holders

BAKER BROS. ADVISORS LP RTW INVESTMENTS, LP Susquehanna Portfolio Strategies, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IDYA on your watchlist

Track score changes the day IDEAYA Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IDYA a good stock to buy?

13F Pro's AI-powered analysis of IDEAYA Biosciences, Inc. (IDYA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IDYA are available on the IDYA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IDYA is classified as a mid company.

Which hedge funds own IDYA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IDYA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IDEAYA Biosciences, Inc.'s investment landscape.